Latest Breaking News On - Ronald perrone - Page 1 : comparemela.com

email article Metformin was both safe and well tolerated in patients with autosomal dominant polycystic kidney disease (ADPKD), the phase II TAME PKD trial found. The parallel-group, randomized trial of 97 participants found no significant increase in gastrointestinal symptoms over 24 months, according to Ronald Perrone, MD, of Tufts Medical Center in Boston, and colleagues. As measured by the Gastrointestinal Symptoms Rating Scale (GSRS), patients on metformin also didn t see any gastrointestinal tolerability issues compared with those on placebo. Lactic acidosis and hypoglycemia were not found to be problematic, Perrone said during a presentation of the late-breaking findings at the virtual National Kidney Foundation Spring Clinical Meeting. However, there was no evidence signal for efficacy to slow progression.

New yorkUnited statesTufts medical centerRonald perronePnational kidney foundation spring clinical meetingNational kidney foundationUniversity of marylandGastrointestinal symptoms rating scaleNational kidney foundation spring clinicalTufts medicalMetformin therapyEase declineKidney functionNew york cityபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்